Abstract
Background: To explore the expression and clinicopathological significance of CD56, CDX2, and LRP16 in intrahepatic cholangiocarcinoma (ICC). Methods: Immunohistochemistry for CD56, CDX2, and LRP16 was performed in 127 cases of ICC. Medical records were reviewed and clinicopathological analysis was performed. Results: CD56 expression was detected in 27 cases (21.3%); CDX2 staining was observed in 33 cases (26.0%); and LRP16 expression was noted in 119 ICC specimens (93.7%). Meanwhile, LRP16 expression was significantly in negative correlation with both CD56 and CDX2 expression. Furthermore, positive expression of CD56 or CDX2 were significantly linked with longer overall survival (OS) for ICC patients; LRP16 positive expression patients had a median survival of 20.2 months, whereas those with negative expression featured a median survival of 74.5 months (P Conclusions: CD56 positive expression, CDX2 positive expression or LRP16 negative expression implied significant survival benefits for ICC patients.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
